๐ก RADAR REPORT
Monday, 16 November 2026 ยท data as of 2026-11-16 20:25 UTC
ACTIVE TRIALS8,737
P3 READOUTS ยท 14D25
P3 READOUTS ยท 30D127
CHANGES ยท 7D37
LATE >6 MONTHS46%
Phase 3 readouts due ยท next 14 days
25 trials with an exact primary-completion date in the next two weeks (127 in the next 30 days).
| Date | Trial | Sponsor | Area | N | vs. original plan |
|---|---|---|---|---|---|
| 2026-11-18 est. | POETYK SjS-1 | Bristol-Myers Squibb $BMY | Immuno | 774 | +0.0 mo |
| 2026-11-18 est. | Drugs-SNPs | Medicine Invention Design, Inc | Oncology | 600 | +30.0 mo |
| 2026-11-20 est. | Pembrolizumab | Merck Sharp & Dohme LLC $MRK | Oncology | 990 | +17.1 mo |
| 2026-11-21 est. | Cabergoline tablets | Changchun GeneScience Pharmaceutical Co., Ltd. | Cardio-Met | 382 | +14.0 mo |
| 2026-11-23 est. | Investigational varicella vaccine | GlaxoSmithKline $GSK | Infectious | 750 | +4.4 mo |
| 2026-11-23 est. | dTpa | GlaxoSmithKline $GSK | Infectious | 102 | โ |
| 2026-11-24 est. | KarXT | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Neuro | 406 | +0.8 mo |
| 2026-11-24 est. | Avelumab | EMD Serono Research & Development Institute, Inc. $MRK.DE | Oncology | 205 | +33.9 mo |
| 2026-11-24 est. | 177Lu-DOTATATE injection | HTA Co., Ltd. | Other | 184 | +0.0 mo |
| 2026-11-25 est. | ICP-332 Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Immuno | 552 | +0.0 mo |
| 2026-11-25 est. | rilzabrutinib | Sanofi $SNY | Cardio-Met | 3 | -0.2 mo |
| 2026-11-26 est. | RUBY | Tesaro, Inc. | Oncology | 785 | +60.0 mo |
| 2026-11-26 est. | MT1013 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Cardio-Met | 424 | +0.0 mo |
| 2026-11-28 est. | Yellow fever vaccine (live) | Sanofi $SNY | Infectious | 2440 | +3.7 mo |
| 2026-11-29 est. | Rimegepant | Pfizer $PFE | Neuro | 723 | +5.9 mo |
| 2026-11-30 est. | D-0502 | InventisBio Co., Ltd | Oncology | 640 | +0.0 mo |
| 2026-11-30 est. | Atezolizumab | Hoffmann-La Roche $ROG.SW | Oncology | 382 | -8.1 mo |
| 2026-11-30 est. | Drug:WD-890 | Zhejiang Wenda Pharma Technology LTD. | Immuno | 375 | โ |
| 2026-11-30 est. | A166 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. $6990.HK | Oncology | 365 | +12.0 mo |
| 2026-11-30 est. | SL1002 | Saol Therapeutics Inc | Neuro | 150 | +0.0 mo |
| 2026-11-30 est. | Neuroncell-EX | Cytopeutics Sdn. Bhd. | Cardio-Met | 80 | +21.7 mo |
| 2026-11-30 est. | GS1191-0445 injection | Gritgen Therapeutics Co., Ltd. | Rare | 50 | +0.0 mo |
| 2026-11-30 est. | TS-172 20~60 mg/day | Taisho Pharmaceutical Co., Ltd. | Other | 34 | โ |
| 2026-11-30 est. | Leniolisib | Pharming Technologies B.V. | Other | 15 | +29.7 mo |
| 2026-11-30 est. | AVTX-803 (L-Fucose) | AUG Therapeutics | Other | 4 | +47.0 mo |
Registry changes ยท last 7 days
Phase 3 / 2-3 trials whose ClinicalTrials.gov record changed (status, readout date, enrollment, sites), plus stops and results posted.
| Trial | Sponsor | Change |
|---|---|---|
| AB-3028 | Arsenal Biosciences, Inc. | Active, not recruiting โ Terminated |
| ICM ADX-2191 injection | Aldeyra Therapeutics, Inc. | readout 2026-12 โ 2029-12 (+36.0 mo) |
| DuraSTAR | GlaxoSmithKline $GSK | readout 2029-12-12 โ 2030-03-13 (+3.0 mo) |
| WILL-EMI | Hoffmann-La Roche $ROG.SW | readout 2027-04-30 โ 2027-10-06 (+5.2 mo) |
| Citicoline eye drops 2% | Omikron Italia S.r.l. | readout 2026-04-01 โ 2029-07-01 (+39.0 mo) |
| RASolute 303 | Revolution Medicines, Inc. $RVMD | readout 2028-06 โ 2028-04 (-2.0 mo) |
| Sinovac rabies vaccine | Sinovac Biotech Co., Ltd | readout 2026-09-30 โ 2026-07-15 (-2.5 mo) |
| Zasocitinib | Takeda $TAK | readout 2033-01-24 โ 2034-07-03 (+17.2 mo) |
| IPAX BrIGHT | Telix Pharmaceuticals (Innovations) Pty Limited | readout 2027-07 โ 2028-07 (+12.0 mo) |
| Liraglutide | Novo Nordisk A/S $NVO | results posted |
| DuraSTAR | GlaxoSmithKline $GSK | enrollment 90 โ 100 |
| Citicoline eye drops 2% | Omikron Italia S.r.l. | enrollment 1000 โ 873 |
| Zasocitinib | Takeda $TAK | enrollment 110 โ 210 |
| KN3835 | Endo USA Inc., a Keenova Therapeutics Company | Not yet recruiting โ Recruiting |
| Citicoline eye drops 2% | Omikron Italia S.r.l. | Recruiting โ Active, not recruiting |
| MOUNTAINEER-03 | Seagen, a wholly owned subsidiary of Pfizer $PFE | Recruiting โ Active, not recruiting |
| Sinovac rabies vaccine | Sinovac Biotech Co., Ltd | Not yet recruiting โ Active, not recruiting |
| ZG005 for Injection | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting โ Recruiting |
| VK2735 | Viking Therapeutics, Inc. $VKTX | Not yet recruiting โ Recruiting |
| VK2735 Oral | Viking Therapeutics, Inc. $VKTX | Not yet recruiting โ Recruiting |
| DLBS1442 | Dexa Medica Group | newly registered |
| Fenebrutinib | Hoffmann-La Roche $ROG.SW | newly registered |
| PINNACLE-MI | Novartis Pharmaceuticals $NVS | newly registered |
| Olpasiran | Amgen $AMGN | sites 252 โ 261 |
| TeLuRide-008 | Eikon Therapeutics | sites 42 โ 52 |
| KN3835 | Endo USA Inc., a Keenova Therapeutics Company | sites 0 โ 4 |
| RAINFOL-04 | Genmab $GMAB | sites 34 โ 69 |
| DuraSTAR | GlaxoSmithKline $GSK | sites 0 โ 1 |
| PERSISTCRSwNP2 | GlaxoSmithKline $GSK | sites 4 โ 7 |
| ZUPREME-5 | Hoffmann-La Roche $ROG.SW | sites 3 โ 11 |
Delay Index
Across 5,352 active trials registered more than a year ago, 46% have moved their readout date by more than 6 months since first registration.
Most often late
| Sponsor | Trials | >6 mo late |
|---|---|---|
| Acerta Pharma BV | 11 | 91% |
| Ionis Pharmaceuticals, Inc. $IONS | 12 | 83% |
| Taiho Oncology, Inc. | 10 | 70% |
| Allist Pharmaceuticals, Inc. | 12 | 67% |
| Seagen, a wholly owned subsidiary of Pfizer $PFE | 12 | 67% |
Most on time
| Sponsor | Trials | On time ยฑ1 mo |
|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | 33 | 88% |
| Ono Pharmaceutical Co., Ltd. $4528.T | 13 | 85% |
| Biocad | 12 | 83% |
| Shanghai JMT-Bio Inc. | 12 | 83% |
| Dizal Pharmaceuticals | 10 | 80% |
FDA this week
New NDA/BLA approvals and Class I drug recalls (last 7 days), and manufacturing (CGMP) or trial-conduct warning letters (last 14 days).
| Type | What | Company | Date |
|---|---|---|---|
| โ Approval | OXDERYS (doxorubicin hydrochloride) | AVYXA HOLDINGS | 2026-11-09 |
| โ Approval | NDA221291 | BAYER HEALTHCARE $BAYN.DE | 2026-11-09 |
| โ Approval | MULTIBIC (multibic) | FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC | 2026-11-09 |
| โ Warning letter | Request for Records/CGMP/API/Adulterated | Nanjing Hanxin Pharmaceutical Technology Co. Ltd. | 2026-11-03 |
| โ Warning letter | CGMP/Finished Pharmaceuticals/Adulterated | USV Private Limited | 2026-11-02 |
New Phase 3 trials ยท last 7 days
30 Phase 3 / 2-3 trials were first posted on ClinicalTrials.gov.
| Trial | Sponsor | Area | N |
|---|---|---|---|
| PINNACLE-MI | Novartis Pharmaceuticals $NVS | Cardio-Met | 10000 |
| Frexalimab | Sanofi $SNY | Neuro | 2500 |
| Fenebrutinib | Hoffmann-La Roche $ROG.SW | Neuro | 1800 |
| AMBITION 3 | Novo Nordisk A/S $NVO | Cardio-Met | 1200 |
| AMBITION4 | Novo Nordisk A/S $NVO | Cardio-Met | 1060 |
| Berobenatide | Pfizer $PFE | Cardio-Met | 900 |
| RC118(Dose 1) plus RC148(Dose 1) | RemeGen Co., Ltd. | Oncology | 680 |
| SYS6010 | CSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HK | Oncology | 585 |
| ABBV-722 | AbbVie $ABBV | Immuno | 580 |
| AMBITION 2 | Novo Nordisk A/S $NVO | Cardio-Met | 450 |
| SYS6010 combined with Enlonstobart | CSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HK | Oncology | 424 |
| QLS5132 | Qilu Pharmaceutical Co., Ltd. | Oncology | 420 |
| NP-101 | Novatek Pharmaceuticals | Oncology | 381 |
| TLX101-Px | Telix Pharmaceuticals (Innovations) Pty Limited | Oncology | 381 |
| RC28-E | RemeGen Co., Ltd. | Cardio-Met | 350 |
Post text
Ready to paste on LinkedIn or X.
๐ก TrialSonar Radar Report ยท 16 Nov 2026 โฑ 25 Phase 3 readouts due in the next 14 days (127 in 30): โข 2026-11-18 โ POETYK SjS-1 (Bristol-Myers Squibb $BMY, Immuno) โข 2026-11-18 โ Drugs-SNPs (Medicine Invention Design, Inc, Oncology) โข 2026-11-20 โ Pembrolizumab (Merck Sharp & Dohme LLC $MRK, Oncology) โข 2026-11-21 โ Cabergoline tablets (Changchun GeneScience Pharmaceutical Co., Ltd., Cardio-Met) โข 2026-11-23 โ Investigational varicella vaccine (GlaxoSmithKline $GSK, Infectious) ๐ Registry changes this week: โข AB-3028 (Arsenal Biosciences, Inc.): Active, not recruiting โ Terminated โข ICM ADX-2191 injection (Aldeyra Therapeutics, Inc.): readout 2026-12 โ 2029-12 (+36.0 mo) โข DuraSTAR (GlaxoSmithKline $GSK): readout 2029-12-12 โ 2030-03-13 (+3.0 mo) โข WILL-EMI (Hoffmann-La Roche $ROG.SW): readout 2027-04-30 โ 2027-10-06 (+5.2 mo) ๐ Delay Index: 46% of active trials (registered >1 yr ago) have pushed their readout >6 months. Most often late: Acerta Pharma BV 91%, Ionis Pharmaceuticals, Inc. 83%, Taiho Oncology, Inc. 70% โ FDA: OXDERYS approved (AVYXA HOLDINGS); NDA221291 approved (BAYER HEALTHCARE); MULTIBIC approved (FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC); warning letter to Nanjing Hanxin Pharmaceutical Technology Co. Ltd.; warning letter to USV Private Limited Full report & live map: https://trialsonar.netlify.app/report/ Data: ClinicalTrials.gov, openFDA, fda.gov. Not investment advice.
Sources: ClinicalTrials.gov (U.S. NLM), openFDA and fda.gov warning letters. Primary completion dates are sponsor-reported and often estimates; readout = last primary-endpoint data collected, not results publication. For information only โ not investment or medical advice. Disclaimer